Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma

Overview of attention for article published in Clinical Cancer Research, December 2018

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (66th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 8 X users

Citations

dimensions_citation: 25 Dimensions

Readers on

mendeley: 40 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 25 publications that cite this research output.

25

The most recent citing publications are shown below. View all 25 publications that cite this research output on Dimensions.

Frequency of Complete Remission With R-CHOP Therapy in Patients With Diffuse Large B Cell Lymphoma

Article in Cureus (April 2024)

The two sides of chromosomal instability: drivers and brakes in cancer

Article in Signal Transduction and Targeted Therapy (March 2024)

Chapter 11 Anticancer drugs acting on signaling pathways, part 2: Inhibitors of serine-threonine kinases and miscellaneous signaling pathways

Book chapter (January 2023)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.